OncLive TV

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Jonathan A. Ledermann, BSc, MD, FRCP, professor of medical oncology, UCL Cancer Institute, University College London, and an honorary consultant medical oncologist, UCL Hospitals, discusses responses to rucaparib (Rubraca) maintenance in ovarian cancer.

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Katherine D. Crew, MD, MS, discusses the results of the APHINITY trial in HER2-positive breast cancer.

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Michael Choi, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Betsy O’Donnell, MD, discusses unanswered questions in multiple myeloma.

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.